Imipenem E Cilastatina Sun

Imipenem and Cilastatin, the active ingredient in Imipenem E Cilastatina Sun, is a carbapenem presented as an intravenous formulation for injection use. It treats a range of serious bacterial infections, including intra‑abdominal, urinary tract, respiratory, skin and soft‑tissue infections, and septicemia, in hospitalized patients.

GNH USA supplies Imipenem E Cilastatina Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Imipenem and Cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

- Complicated intra‑abdominal infections: achieves bacterial eradication and improves clinical cure rates. - Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection. - Nosocomial pneumonia: provides effective coverage against hospital‑acquired respiratory pathogens. - Skin and soft‑tissue infections: treats severe cellulitis and wound infections. - Septicemia: rapidly reduces bacteremia and supports patient recovery.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or pruritus. - Headache: transient cephalic pain. - Elevated liver enzymes: mild transaminase increase. - Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Nephrotoxicity: renal function decline in susceptible individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Thrombophlebitis: inflammation of veins at infusion site.

Use of Imipenem and Cilastatin requires careful clinical assessment. - Renal function: adjust dosing in patients with impaired renal clearance. - History of seizures: monitor for neurotoxicity and avoid high doses. - Hypersensitivity: avoid in individuals with known carbapenem allergy. - Concomitant valproic acid: may reduce serum valproate levels, risking seizure breakthrough. - Pregnancy: prescribe only when benefits outweigh potential risks. - Store at room temperature: keep in original container, protect from light and moisture.

Imipenem and Cilastatin may interact with several agents.

Major Interactions (Avoid): - Valproic acid: significant reduction of serum valproate, increasing seizure risk. - Renal dehydropeptidase inhibitors: may increase imipenem toxicity. - Probenecid: can alter renal excretion, affecting drug levels.

Moderate Interactions (Monitor Closely): - Aminoglycosides: increased risk of nephrotoxicity; monitor renal function. - Loop diuretics: watch electrolyte balance and renal status. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation parameters.